Clinical Study
Restless Legs Syndrome and Its Associated Risk Factors in Parkinson’s Disease
Table 1
Baseline characteristics of study population.
| | |
| Age, years, mean (SD) | 64.8 (9.0) | Sex, n (%) | | Male | 60 (53.1) | Female | 53 (46.9) | Ethnicity, n (%) | | Malay | 32 (28.3) | Chinese | 71 (62.8) | Indian | 8 (7.1) | Others | 2 (1.8) | Duration of illness of PD, years | 5 (2.0–8.0) | Levodopa dose, mg | 300 (450) | LEU of dopamine agonist, mg | 0 (75) | Total LEU, mg | 350 (480) | Hoehn and Yahr stage | 2 (2.0-3.0) | Stage 1, n (%) | 26 (23) | Stage 2, n (%) | 54 (48.7) | Stage 3, n (%) | 30 (26.5) | Stage 4, n (%) | 2 (1.8) |
|
|
Data is expressed as median (IQR) unless otherwise stated. LEU: levodopa equivalence unit; total LEU: levodopa plus LEU of dopamine agonist.
|